Blanket Purchase Agreement 36F79722D0161-36E79724A0001
Award Date
10/18/23
Last Date to Order
10/17/25
Federal Agency
National Acquisition Center
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) has awarded a $1.7M Federal Supply Schedule (FSS) contract to Amneal Pharmaceuticals of New York, LLC, a for-profit limited liability company that manufactures pharmaceutical products. The FSS contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, enables the VA to procure a variety of drugs, pharmaceuticals, and hematology-related products from Amneal through task orders over the 5-year contract period. Separately, the VA has also...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs National Acquisition Center to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $3.1 million single-award contract establishes an Indefinite Delivery Vehicle (IDV) for the procurement of orexin inhibitors, a class of sleep-regulating medications, over a one-year base period with four option years. This BPA aims to ensure the availability of...
The Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) to Jazz Pharmaceuticals, Inc., a global biopharmaceutical company, to provide specialty pharmaceutical products such as Xyrem, Xywav, and sodium oxybate formulations. The BPA, valued at up to $150 million, allows the VA to efficiently procure needed medications to support healthcare services for veterans at VA medical facilities nationwide....
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The single-award BPA (Contract #36E79724A0005) has a ceiling value of $5,500,000 and is effective from January 18, 2024 to September 19, 2024. It was awarded without the use of a set-aside and enables the...
This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs (VA) to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $300,000 contract, with a period of performance through September 2027, is for the provision of drugs, pharmaceuticals, and hematology-related products under Schedule 65 I B. Additionally, Idorsia Pharmaceuticals US Inc. holds a $3.1 million Blanket Purchase Agreement (BPA) with the...
The Department of Veterans Affairs awarded a multiple-award federal supply schedule contract to Amryt Pharmaceuticals Inc. with a potential value of $225,000. The schedule is for pharmaceuticals and hematology-related products under contract number 65 IB. This enables ordering through September 2028. Additionally, the Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Amryt Pharmaceuticals with a value of up to $1,000,000. The BPA...
The National Acquisition Center, a civilian federal agency, has awarded a single-award Blanket Purchase Agreement (BPA) to Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals, for the procurement of the controlled substance sodium oxybate. The contract has a ceiling value of $38,500,000 and a period of performance through February 6, 2026. Hikma Pharmaceuticals USA Inc. is a foreign-owned, for-profit pharmaceutical manufacturer registered in the System for Award...
The Department of Veterans Affairs National Acquisition Center awarded a Blanket Purchase Agreement (BPA) to Jazz Pharmaceuticals, Inc. for the delivery of specialty pharmaceutical products, primarily the sleep disorder medication Xyrem. The $150 million BPA is issued under Jazz Pharmaceuticals' Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract, allowing the VA to efficiently procure needed medications for its healthcare facilities. Four task orders worth up to $717,519 have...
The National Acquisition Center of the U.S. Department of Veterans Affairs (VA) has awarded a $32,500,000 Blanket Purchase Agreement (BPA) to Ardelyx, Inc., a pharmaceutical company, for the supply of XPHOZAH (tenapanor), a medication used to treat hyperphosphatemia in patients on dialysis. This single-award BPA, which has an ultimate completion date of April 29, 2026, allows VA medical centers nationwide to efficiently procure the XPHOZAH medication as needed through delivery orders. Ardelyx,...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Nobelpharma America, LLC, a foreign-owned, self-certified small disadvantaged business. The single-award BPA, valued at up to $4.5 million, is for the delivery of the medication HYFTOR through June 2026. HYFTOR is likely used to treat conditions like post-traumatic stress disorder and chronic pain among veterans. In addition to this BPA, Nobelpharma America, LLC...